Mechanism addresses side-effect problem in protein-degradation therapies
1 Oct 30 · 9d ago · 5 articles · 1 post · 3 sources · development 1 of 1
The RuPHOTAC technology solves a critical limitation of conventional PROTACs: their inability to target specific tissues. Most disease-associated proteins also perform important functions in healthy cells, so systemic protein degradation causes unwanted side effects. RuPHOTACs enable selective activation only in illuminated tissue.
“The problem is there are very few targets—like aberrant proteins—that are only found in cancer. Most of the time, the proteins are important for our healthy tissues too. So we need a 'cage'; that is, a way to control when and where these PROTACs are activated.”
Edith C. (Phoebe) GlazerEdith C. (Phoebe) Glazer Professor of chemistry, North Carolina State University
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
Reported in the same hours no headline names this development itself — these 1 claim were published in its stretch
-
first by Mirage News, 9d ago · also The National Tribune, Google News · Health
2 more headlines
- Researchers create light-activated cages for 'protein killer' molecules Phys.org · 9d ago
- Light-activated molecular cages offer precise control over protein degradation - News-Medical Google News · Health · 8d ago
What people said 1 voice · verbatim
-
S
RuPHOTACs are light-activated molecular cages that keep protein-degrading drug molecules inactive until they are exposed to low-energy red light. # MolecularChemistry # Photochemistry # Pharmacology # CellularBiology # sflorg https://www. sflorg.com/2026/10/chm10292601 .html
All 1 developments of Researchers develop light-activated protein-degradation… →
Google NewsMastodonNewswires